Literature DB >> 12145541

Detection of JC virus type 1 in peripheral lymphocytes, brain and cerebrospinal fluid from two Korean AIDS patients with progressive multifocal leukoencephalopathy.

Byung-Hoon Jeong1, Jae-Kwang Jin, Eun-Kyoung Choi, Kyung-Hoon Kim, Kang-Won Choi, Myoung-Don Oh, Ki-Chul Shin, Yong-Sun Kim.   

Abstract

The human polyomavirus JC virus (JCV) is the etiologic agent of the fatal demyelinating central nervous system disease progressive multifocal leukoencephalopathy (PML), which occurs in 4-7% of AIDS patients. Two Korean AIDS patients with PML were assayed for JCV, and the virus was genotyped by polymerase chain reaction, DNA sequencing and phylogenetic analysis. Using immunohistochemical analysis, we also examined the distribution of JCV antigen in the brains of the patients. The JCV genome was detected in peripheral lymphocytes, brain and cerebrospinal fluid from these Korean PML patients. Although type 2 is the most common genotype in Asia, the genotype of the JCV in these two AIDS patients was characterized as type 1, which is of European origin. We found that JCV antigen was selectively detected in oligodendrocytes and astrocytes of the brains from these patients. Compared to the prototype type 1 (Mad-1), two different nucleotides (G-->C) in the KOR-1 strain identified here were found at positions 2488 and 2490 of the major capsid protein VP1 gene. In summary, this is the first report of PML in Korean AIDS patients; it is also the first isolation of JCV type 1 in PML in East Asians. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145541     DOI: 10.1159/000063229

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  1 in total

1.  Molecular analysis of JC virus genotypes circulating among the Italian healthy population.

Authors:  Elisabetta Pagani; Serena Delbue; Roberta Mancuso; Elisa Borghi; Letizia Tarantini; Pasquale Ferrante
Journal:  J Neurovirol       Date:  2003-10       Impact factor: 2.643

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.